Hans-Peter Gerber Purchases 17,000 Shares of Sutro Biopharma (NASDAQ:STRO) Stock

Key Points

• Hans-Peter Gerber, an insider at Sutro Biopharma, purchased 17,000 shares at $0.80 each, increasing his total holdings by 31.00% to 71,832 shares.
• Sutro Biopharma recently reported quarterly earnings of ($0.14) per share, surpassing estimates and showing significant revenue growth to $63.74 million.
• Recent analyst ratings have varied, with Wells Fargo lowering its price target from $4.00 to $3.00 while other analysts maintain an average rating of "Hold" with a consensus target price of $4.47.

Sutro Biopharma, Inc. (NASDAQ:STRO - Get Free Report) insider Hans-Peter Gerber acquired 17,000 shares of Sutro Biopharma stock in a transaction that occurred on Wednesday, October 15th. The shares were purchased at an average cost of $0.80 per share, with a total value of $13,600.00. Following the completion of the acquisition, the insider owned 71,832 shares of the company's stock, valued at $57,465.60. The trade was a 31.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Sutro Biopharma Stock Performance

STRO stock traded up $0.03 during midday trading on Thursday, hitting $0.81. 722,769 shares of the stock were exchanged, compared to its average volume of 1,116,574. The stock's 50-day moving average price is $0.88 and its 200-day moving average price is $0.83. The stock has a market cap of $68.41 million, a price-to-earnings ratio of -0.32 and a beta of 1.61. Sutro Biopharma, Inc. has a fifty-two week low of $0.52 and a fifty-two week high of $4.60.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.25. The company had revenue of $63.74 million during the quarter, compared to the consensus estimate of $14.55 million. Sutro Biopharma had a negative return on equity of 852.70% and a negative net margin of 201.32%. Research analysts anticipate that Sutro Biopharma, Inc. will post -2.92 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Wells Fargo & Company dropped their price target on Sutro Biopharma from $4.00 to $3.00 and set an "equal weight" rating for the company in a research report on Tuesday, August 12th. Wall Street Zen raised Sutro Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, September 13th. Finally, Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Sutro Biopharma in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $4.47.

Institutional Trading of Sutro Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the company. Catalyst Funds Management Pty Ltd acquired a new stake in Sutro Biopharma during the second quarter valued at approximately $27,000. Cerity Partners LLC acquired a new stake in shares of Sutro Biopharma during the 1st quarter worth approximately $25,000. Vontobel Holding Ltd. raised its position in shares of Sutro Biopharma by 100.0% during the 1st quarter. Vontobel Holding Ltd. now owns 50,000 shares of the company's stock worth $33,000 after purchasing an additional 25,000 shares during the period. Savant Capital LLC acquired a new stake in shares of Sutro Biopharma during the 2nd quarter worth approximately $37,000. Finally, CWM LLC raised its position in shares of Sutro Biopharma by 73.2% during the 2nd quarter. CWM LLC now owns 56,657 shares of the company's stock worth $40,000 after purchasing an additional 23,941 shares during the period. Institutional investors and hedge funds own 96.99% of the company's stock.

About Sutro Biopharma

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.